Long-Term Survival and Treatment Patterns in Resectable Escc in East Asia: A Comprehensive Study From the International Esodata-Study-Group (Dragon Study)

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Retrospective cohort study shows improved overall survival in ESCC patients with neoadjuvant therapy, indicating its effectiveness.

Neoadjuvant therapy significantly improves overall survival in ESCC patients, with a 5-year overall survival rate of 70.8%.
In a study involving 2482 patients, the 5-year disease-free survival rate was 71.1%, highlighting effective treatment strategies.
The analysis included clinical and pathological data collected from high-volume centers in East Asia over a median follow-up of 36.5 months.
Findings suggest that collaborative research leveraging high-quality data could advance the esophageal cancer TNM staging system.

Leng et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark